fastGEN EGFR/HER2 Cancer 32-kit

Description

The fastGEN EGFR/HER2 Cancer Kit is a new NGS kit designed to detect key mutations in the EGFR and HER2 (ERBB2) genes that play a crucial role in non-small cell lung cancer (NSCLC).

Detection of resistant and rare mutations

The kit enables the detection of activating mutations in the EGFR gene, particularly exon 19 deletions and the L858R point mutation in exon 21, which are associated with sensitivity to EGFR tyrosine kinase inhibitors (TKIs). In addition to these common variants, it also identifies less frequent mutations such as G719X, L861Q, and insertions in exon 20 (Ex20ins). While G719X and L861Q may show variable response, Ex20ins mutations are typically resistant to conventional TKIs. The analysis covers both sensitizing and resistant mutations, supporting the selection of the most appropriate targeted therapy. For the HER2 gene, the kit detects point mutations and insertions in exon 20, which are involved in tumor progression and represent potential targets for therapies such as trastuzumab deruxtecan.

Compatibility

Compatible with all Illumina platforms, for other platforms use conversion kit.

Bioinformatic analysis software: GENOVESA

The GENOVESA fastGEN software module, available online, can be used to analyse sequencing data. It is an all-in-one cloud solution for raw data analysis (FASTQ files), with technical and application support.

Visit GENOVESA

Specifications

• Product: fastGEN EGFR/HER2 Cancer 32-kit
• Cat. No.: RDNGS0020-32 — 32 samples (1 kit)
• Regulatory status: RUO
• Type: fastGEN
• Species: Human
• Other names: EGFR, Epidermal Growth Factor Receptor, HER2
• Research topic: Oncology
• Reconstitution: No
• Applications: Isolated DNA